Archived Bulletins

February 28, 2018

Published: February 28, 2018
Category: Trials

"POSITIVE" (CCTG MAC18 / ALLIANCE A221405) is a unique trial which is collecting information prospectively on disease and pregnancy outcome after interrupting endocrine therapy in women with endocrine responsive early breast cancer who wish to have a baby. The lead group have r

Read More

Published: February 28, 2018
Category: Group updates

The Canadian Cancer Trials Group (CCTG), as a major stakeholder, has been invited to provide input on the Health Canada draft of GUI-0100: Guidance Document - Part C, Division 5 of the Food and Drug Regulations "Drugs for Clinical Trials Involving Human Subjects." As a valued member of CCTG we would like to request your input to the CCTG response.

Read More

February 14, 2018

Published: February 14, 2018
Category: Trials

CCTG clinical trials IND213, LY15 and MA31 have been permanently closed.

Read More

Published: February 14, 2018
Category: Group updates
The 2018 Annual Spring Meeting of Participants

The 2018 Annual Spring Meeting of Participants is happening the weekend of April 27 – 29 at the Chelsea Hotel in Toronto. Funded and non-funded invitations are coming soon.

Read More

Published: February 14, 2018
Category: Publications
CCTG trials listed in research publications or citations

January 31, 2018

Published: January 31, 2018
Category: Trials

The CCTG HN.9 study has been centrally activated in Canada, as of January 31.

HN.9  is a Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), 2018.

Read More

Published: January 31, 2018
Category: Trials
The MAP3 trial is considered permanently closed. MAP3 is a Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
For further information please contact Christine Bertrim
Read More

Published: January 31, 2018
Category: Group updates

The Central Operations and Statistics Office is seeking nominations for the 2018 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.

We are seeking nominations for the following Recognition Awards:

Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research

Read More